文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

SPIRE:SGI-110联合顺铂和吉西他滨治疗包括膀胱癌在内的实体恶性肿瘤——Ib/IIa期开放标签临床试验方案

SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
PubMed 文献 · Trials · 2018-04-03

SPIRE是一项Ib/IIa期开放标签临床试验,旨在评估DNA甲基转移酶抑制剂SGI-110联合吉西他滨和顺铂(GC)方案治疗晚期实体瘤及作为膀胱尿路上皮癌新辅助治疗的安全性、耐受性及推荐II期剂量(RP2D)。Ib期采用改良滚动六剂量递增设计,最多纳入36例晚期实体瘤患者;IIa期随机对照剂量扩展纳入20例膀胱尿路上皮癌患者,1:1随机接受GC联合或不联合RP2D剂量SGI-110。主要终点为RP2D,次要终点包括毒性、药代动力学/药效生物标志物及病理完全缓解率。

要点

  • SGI-110联合GC方案在Ib期确定RP2D,Ib期采用改良滚动六剂量递增设计。
  • IIa期在膀胱尿路上皮癌新辅助治疗中随机比较GC联合或不联合SGI-110的疗效与安全性。
  • GC常规剂量为顺铂70 mg/m2(第8天)和吉西他滨1000 mg/m2(第8、15天),21天为一周期。

核心结论

  • SPIRE试验旨在为SGI-110联合GC化疗是否安全且具有生物学有效性提供证据,为后续II/III期新辅助治疗膀胱尿路上皮癌及其他GC治疗癌症的试验奠定基础。

研究设计与样本

  • Ib期采用改良滚动六剂量递增设计,最多纳入36例晚期实体瘤患者,确定SGI-110联合GC的RP2D。
  • IIa期纳入20例膀胱尿路上皮癌患者,1:1随机接受GC联合或不联合RP2D剂量SGI-110的新辅助治疗。
  • SGI-110通过皮下注射给药,第1-5天;GC每21天重复,顺铂70 mg/m2静脉输注第8天,吉西他滨1000 mg/m2静脉输注第8和15天。

关键数值与推荐

  • Ib期主要终点为SGI-110联合GC的RP2D。
  • IIa期次要终点包括毒性特征、SGI-110药代动力学和药效生物标志物、病理完全缓解率。
  • 分析未设定正式统计比较的效力,将采用描述性统计按治疗组描述毒性、疗效和转化终点率。

局限性

  • IIa期分析未设定正式统计比较的效力,仅采用描述性统计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer , Cancer Research UK, Accessed 26 Mar 2018). Cisplatin-based chemotherapy is standard of care therapy for UBC for both palliative first-line treatment of advanced/metastatic disease and radical neoadjuvant treatment of localised muscle invasive bladder cancer. However, cisplatin resistance remains a critical cause of treatment failure and a barrier to therapeutic advance in UBC. Based on supportive pre-clinical data, we hypothesised that DNA methyltransferase inhibition would circumvent cisplatin resistance in UBC and potentially other cancers. METHODS: The addition of SGI-110 (guadecitabine, a DNA methyltransferase inhibitor) to conventional doublet therapy of gemcitabine and cisplatin (GC) is being tested within the phase Ib/IIa SPIRE clinical trial. SPIRE incorporates an initial, modified rolling six-dose escalation phase Ib design of up to 36 patients with advanced solid tumours followed by a 20-patient open-label randomised controlled dose expansion phase IIa component as neoadjuvant treatment for UBC. Patients are being recruited from UK secondary care sites. The dose escalation phase will determine a recommended phase II dose (RP2D, primary endpoint) of SGI-110, by subcutaneous injection, on days 1-5 for combination with GC at conventional doses (cisplatin 70 mg/m2, IV infusion, day 8; gemcitabine 1000 mg/m2, IV infusion, days 8 and 15) in every 21-day cycle. In the dose expansion phase, patients will be randomised 1:1 to GC with or without SGI-110 at the proposed RP2D. Secondary endpoints will include toxicity profiles, SGI-110 pharmacokinetics and pharmacodynamic biomarkers, and pathological complete response rates in the dose expansion phase. Analyses will not be powered for formal statistical comparisons and descriptive statistics will be used to describe rates of toxicity, efficacy and translational endpoints by treatment arm. DISCUSSION: SPIRE will provide evidence for whether SGI-110 in combination with GC chemotherapy is safe and biologically effective prior to future phase II/III trials as a neoadjuvant therapy for UBC and potentially in other cancers treated with GC. TRIAL REGISTRATION: EudraCT Number: 2015-004062-29 (entered Dec 7, 2015) ISRCTN registry number: 16332228 (registered on Feb 3, 2016).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Crabb S, Danson SJ, Catto JWF, et al. SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. Trials. 2018. PMID: 29615077. doi:10.1186/s13063-018-2586-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。